Revenue: As of FY2026 Q1, the actual value is USD 31.59 K, beating the estimate of USD 0.EPS: As of FY2026 Q1, the actual value is USD -0.15.EBIT: As of FY2026 Q1, the actual value is USD -1.274 M.<h3>Segment Revenue</h3><ul><li>Total Revenue: Vyome Holdings, Inc. reported total revenue of $31,591 for the three months ended March 31, 2026, a decrease from $198,581 for the same period in 2025.</li><li>Pharmaceutical Segment: Revenue for the Pharmaceutical segment was $31,591 for the three months ended March 31, 2026, down from $198,581 in the prior year period. This included $25,465 from product sales and $6,126 from royalty income for Q1 2026, compared to $76,727 from product sales and $4,954 from royalty income in Q1 2025. Licensing and milestone fees for Luliconazole were $0 in Q1 2026, compared to $116,900 in Q1 2025.</li><li>Biotechnology Segment: The Biotechnology segment generated $0 revenue for both periods.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: Total gross profit was $16,645 for the three months ended March 31, 2026, a decrease from $154,419 for the same period in 2025. The Pharmaceutical segment contributed $16,645 to gross profit in Q1 2026, down from $154,419 in Q1 2025.</li><li>Operating Expenses: Total operating expenses increased to $1,146,585 for Q1 2026 from $353,417 for Q1 2025.<ul><li>Research and Development (R&amp;D): R&amp;D expenses significantly increased to $666,405 for Q1 2026 from $90,268 for Q1 2025. The Biotechnology segment’s R&amp;D expenses were $636,769 in Q1 2026, up from $75,437 in Q1 2025, while the Pharmaceutical segment’s R&amp;D expenses were $29,636 in Q1 2026, up from $14,831 in Q1 2025. This increase was primarily due to focusing resources on regulatory consulting and CMC preparation for the VT-1953 project.</li><li>Selling, General and Administrative (SG&amp;A): SG&amp;A expenses increased to $477,575 for Q1 2026 from $259,626 for Q1 2025. The Biotechnology segment’s SG&amp;A expenses were $458,936 in Q1 2026, up from $236,537 in Q1 2025, and the Pharmaceutical segment’s SG&amp;A expenses were $18,639 in Q1 2026, down from $23,089 in Q1 2025.</li><li>Depreciation and Amortization: Depreciation and amortization decreased to $2,605 for Q1 2026 from $3,523 for Q1 2025, with these expenses fully attributed to the Biotechnology segment.</li></ul></li><li>Operating Loss: Total operating loss for Vyome Holdings, Inc. was -$1,129,940 for Q1 2026, an increase from -$198,998 for Q1 2025.</li><li>Net Loss: The net loss increased to -$985,521 for Q1 2026 from -$293,974 for Q1 2025. The Biotechnology segment incurred a net loss of -$953,892 in Q1 2026, compared to -$410,473 in Q1 2025. The Pharmaceutical segment incurred a net loss of -$31,629 in Q1 2026, compared to a net income of $116,499 in Q1 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was -$1,435,966 for the three months ended March 31, 2026, compared to -$203,535 for the same period in 2025, primarily driven by net losses and changes in working capital.</li><li>Net Cash Generated from Financing Activities: Net cash generated from financing activities was $5,288,868 for Q1 2026, mainly from the sale of common stock via an At-The-Market (ATM) offering, compared to $160,000 for Q1 2025 from convertible notes.</li><li>Cash and Cash Equivalents: Vyome Holdings, Inc. had $8,795,783 in cash and cash equivalents as of March 31, 2026, an increase from $58,370 at March 31, 2025.</li></ul><h3>Future Outlook and Strategy</h3>Vyome Holdings, Inc. anticipates that existing cash, combined with proceeds from the private placement offering and ATM facility, will fund operating expenses and capital expenditures for at least 15 months, including the initiation of the pivotal trial for its lead candidate, VT-1953. However, these funds are not sufficient to complete the VT-1953 trial or develop other product candidates. The company expects to finance future operations through equity offerings, debt financings, or strategic collaborations, while also planning to increase R&amp;D costs for its product candidates.

Vyome | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 31.59 K